211311-95-4
基本信息
N-[2-[4-(4-氰基苯基)苯基]丙基]丙烷-2-磺酰胺
CS-2739
LY404187
LY-404187
LY 404187
N-2-(4-(4-Cyanophenyl)phenyl)propyl-2-propanesulfonamide
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide
N-[2-[4-(4-Cyanophenyl)phenyl]propyl]propane-2-sulfonamide
N-[2-(4'-Cyano[1,1'-biphenyl]-4-yl)propyl]-2-propanesulfonamide
N-(2-(4'-Cyano-[1,1'-biphenyl]-4-yl)propyl)propane-2-sulfonaMide
2-Propanesulfonamide, N-[2-(4'-cyano[1,1'-biphenyl]-4-yl)propyl]-
物理化学性质
| 沸点 | 519.0±60.0 °C(Predicted) |
| 密度 | 1.19±0.1 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | DMF: 15mg/mL; DMSO: 15mg/mL; DMSO:PBS (pH 7.2) (1:4): 0.2mg/mL; Ethanol: 3mg/mL |
| 酸度系数(pKa) | 11.24±0.40(Predicted) |
| 形态 | 固体 |
| 颜色 | White to off-white |
N-[2-(4'-氰基联苯-4-基)丙基]-2-丙烷磺酰胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-13456 | N-[2-(4'-氰基联苯-4-基)丙基]-2-丙烷磺酰胺 LY-404187 | 211311-95-4 | 1 mg | 400元 |
| 2025/02/08 | HY-13456 | N-[2-(4'-氰基联苯-4-基)丙基]-2-丙烷磺酰胺 LY-404187 | 211311-95-4 | 5 mg | 1000元 |
| 2025/02/08 | HY-13456 | N-[2-(4'-氰基联苯-4-基)丙基]-2-丙烷磺酰胺 LY-404187 | 211311-95-4 | 10 mM * 1 mLin DMSO | 1100元 |
常见问题列表
EC50: 5.65 µM (GluR1i), 0.15 µM (GluR2i), 1.44 µM (GluR2o), 1.66 µM (GluR3i), 0.21 µM (GluR4i)
LY-404187 (3-10 nM) potentiates glutamate-evoked inward currents in human GluR4 transfected HEK293 cells.
LY-404187 (0.03-10 µM) selectively enhances glutamate-evoked currents through AMPA receptor/channels of acutely isolated pyramidal neurons with considerably greater potency (EC
50
=1.3±0.3 µM) and efficacy (E
max
=45.3±8.0-fold increase) .
LY-404187 does not affect the magnitude or time course of wholecell K
+
or Na
+
currents in pre frontal cortex (PFC) pyramidal neurons at concentrations of 10 µM.
LY-404187 (0.5 mg/kg; s.c for 11 days) can prevent MPTP-induced neurotoxicity in mice.
LY-404187 (0.5 mg/kg; s.c. for 28 days) attenuates apomorphine-induced contraversive rotations and affords significant protection against the loss of tyrosine hydroxylase positive nigral cell bodies.
LY-404187 (0.1 or 0.5 mg/kg; s.c. for 14 days) affords functional, neurochemical and histological protection after infusion of 6-hydroxydopamine into the substantia nigra in rats.
LY-404187 (0.5 mg/kg; s.c. for 14 days) delayed treatment provides functional and histological improvement, suggesting a trophic action as administration is initiated after cell death.
LY-404187 (0.1 and 0.5 mg/kg; s.c. for 14 days) increases GAP-43 immunoreactivity in the striatum in a dose-dependent manner.
| Animal Model: | Male C57BL/6J mice (20-25 g) are challenged with MPTP on day 8 |
| Dosage: | 0.5 mg/kg |
| Administration: | S.c; twice daily on weekdays and once daily at weekends for 11 days |
| Result: |
Attenuated the loss of tyrosine hydroxylase immunoreactivity in the substantia nigra.
No significant change in tyrosine hydroxylase immunoreactivity in the dorsal and ventral striatum. |